QUICK SEARCH:   [advanced] Author: Keyword(s):
Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents

Help viewing high resolution images Return to article

Fig. 5. FGF2 and Ang-1 have additive effects on the maintenance of CLS in the absence of VEGF. (A) Phase-contrast micrographs of BREC after treatment for 2 days with VEGF plus FGF2 and an additional 2 days of VEGF neutralization, in the absence or presence of Ang1. (B) Neutralization of VEGF significantly decreased the length of CLS (^*P<0.0001 compared to 2 days treatment with VEGF plus FGF2), whereas Ang1 provided partial protection from the regression, an effect not antagonized by Ang2 (^**P<0.04). The angiopoietins did not significantly alter proliferation from that with VEGF-Trap plus FGF2 alone. (C) Phase-contrast micrographs of BREC after treatment for 2 days in the presence of VEGF followed by VEGF neutralization for an additional 2 days, in the absence or presence of Ang1. (D) All treatments with VEGF-Trap led to a significant reduction of CLS compared with baseline (VEGF after 2 days, P<0.0001). In combination with VEGF neutralization, Ang1 treatment led to significantly more CLS (^*P<0.03 vs no angiopoietins), an effect that was not influenced by Ang2. Addition of FGF2 or angiopoietins did not significantly alter proliferation from that with VEGF-Trap alone. Concentrations of factors used: 25 ng/ml VEGF, 2.5 ng/ml FGF2, 1 ng/ml TGFβ1, 500 ng/ml Ang1, 500 ng/ml Ang2, and 1 µg/ml VEGF-Trap. Bar, 100 µm.

Return to article